LGND
HEALTHCARELigand Pharmaceuticals Inc - Class B
$232.55+0.25 (+0.11%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LGND Today?
No stock-specific AI insight has been generated for LGND yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$98.89$247.38
$232.55
Fundamentals
Market Cap$2.8B
P/E Ratio37.9
EPS$6.13
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.5%
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding12.1M
LGND News
23 articles- Ligand Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Ligand Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing AgreementYahoo Finance·May 6, 2026
- Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing AgreementYahoo Finance·May 6, 2026
- Ligand to Participate in May Investor ConferencesYahoo Finance·May 5, 2026
- Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 MillionMotley Fool·May 2, 2026
- LGND: XOMA Buy Adds 100+ AssetsYahoo Finance·Apr 29, 2026
- XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law FirmGlobeNewswire Inc.·Apr 28, 2026
- Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated DiscountYahoo Finance·Apr 28, 2026
- XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?Yahoo Finance·Apr 28, 2026
- Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS OutlookMarketbeat·Apr 27, 2026
- Royalty Powerhouse: Ligand And Xoma Unite In $739 Million DealYahoo Finance·Apr 27, 2026
- Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 MillionBenzinga·Apr 27, 2026
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of XOMA Royalty Corporation (NASDAQ: XOMA)GlobeNewswire Inc.·Apr 27, 2026
- Ligand Pharmaceuticals buying Xoma Royalty for $739 millionQz·Apr 27, 2026
- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty AggregatorYahoo Finance·Apr 27, 2026
- Ligand to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 22, 2026
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGSYahoo Finance·Apr 14, 2026
- Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout AgreementMotley Fool·Apr 6, 2026
- Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past YearYahoo Finance·Apr 4, 2026
- CLO Sells LGND 5,000 Shares for $1.0 MillionMotley Fool·Mar 31, 2026
- Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to KnowThe Motley Fool·Mar 27, 2026
- Ligand Advances Strategic Growth with Expanded and Strengthened Business Development TeamYahoo Finance·Mar 26, 2026
All 23 articles loaded
Price Data
Open$0.00
Previous Close$232.30
Day High$0.00
Day Low$0.00
52 Week High$247.38
52 Week Low$98.89
52-Week Range
$98.89$247.38
$232.55
Fundamentals
Market Cap$2.8B
P/E Ratio37.9
EPS$6.13
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.5%
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding12.1M
About Ligand Pharmaceuticals Inc - Class B
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—